SHP2 participated in the regulation of TGF‐β1‐mediated EMT in A549 cells, and targeting SHP2 may reverse EMT in KRAS‐mutant NSCLC.[57] Consistent with this, the SHP2 inhibitor, SHP099, partially reversed EMT and reduced the malignant phenotype of KRAS‐mutant cells, whereas embelin reduced the migratory and invasive abilities, expression of mesenchymal marker proteins, and increased epithelial cell‐specific proteins in a concentration‐dependent manner. Here, KRAS is linked to non-small cell lung carcinoma.